405 related articles for article (PubMed ID: 27591329)
1. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Kronbichler A; Neumann I; Mayer G
Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
[TBL] [Abstract][Full Text] [Related]
2. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Zhang X; Ji L; Yang L; Tang X; Qin W
Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720
[TBL] [Abstract][Full Text] [Related]
3. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
4. Con: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Fernandez Nieto M; Jayne DR
Nephrol Dial Transplant; 2016 Oct; 31(10):1567-71. PubMed ID: 27591328
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
Lee YH; Song GG
Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors in systemic lupus erythematosus.
Mok CC
Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):429-438. PubMed ID: 29224682
[TBL] [Abstract][Full Text] [Related]
9. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
11. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Fanouriakis A; Kostopoulou M; Cheema K; Anders HJ; Aringer M; Bajema I; Boletis J; Frangou E; Houssiau FA; Hollis J; Karras A; Marchiori F; Marks SD; Moroni G; Mosca M; Parodis I; Praga M; Schneider M; Smolen JS; Tesar V; Trachana M; van Vollenhoven RF; Voskuyl AE; Teng YKO; van Leew B; Bertsias G; Jayne D; Boumpas DT
Ann Rheum Dis; 2020 Jun; 79(6):713-723. PubMed ID: 32220834
[TBL] [Abstract][Full Text] [Related]
12. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
13. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis.
Peleg Y; Bomback AS; Radhakrishnan J
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1066-1072. PubMed ID: 32152065
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
[TBL] [Abstract][Full Text] [Related]
16. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
17. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy.
Mao Y; Yin L; Huang H; Zhou Z; Chen T; Zhou W
J Int Med Res; 2019 Jan; 47(1):105-113. PubMed ID: 30208769
[TBL] [Abstract][Full Text] [Related]
18. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.
Mok CC; Ho LY; Ying SKY; Leung MC; To CH; Ng WL
Ann Rheum Dis; 2020 Aug; 79(8):1070-1076. PubMed ID: 32448782
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
